Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07155057 · ClinicalTrials.gov registry record · NA
Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery
A NA study of Dry Eye Disease (DED), sponsored by Vance Thompson Vision.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07155057 is a NA study of Dry Eye Disease (DED) that is actively recruiting participants, run by Vance Thompson Vision. The registered enrollment target is 60 participants, below the 471-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07155057, a NA study of Dry Eye Disease (DED), is actively recruiting participants, sponsored by Vance Thompson Vision.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
To review how patients report using a hyaluronate crosslinked canalicular gel placed before cataract surgery
Conditions Studied
Interventions
- DEVICE Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML
Study Locations (1)
South Dakota
- Vance Thompson Vision Clinic, Prof. LLC - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07155057
The ClinicalTrials.gov registry entry for NCT07155057 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 471-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (87% lower). The listed sponsor is Vance Thompson Vision, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease (DED) appearing as the primary indexed condition, and to 1 intervention - of which Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML is the first listed.
NCT07155057 reports 1 study location spanning 1 distinct geographic area - top geographies include South Dakota.
Frequently Asked Questions
What is clinical trial NCT07155057 about?
NCT07155057 is a clinical study titled "Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery". To review how patients report using a hyaluronate crosslinked canalicular gel placed before cataract surgery
What is the current status of trial NCT07155057?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-09-03. Estimated completion is 2026-12.
What conditions does trial NCT07155057 study?
This clinical trial studies the following conditions: Dry Eye Disease (DED).
What interventions are being tested in trial NCT07155057?
The interventions under investigation include: Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML (DEVICE).
Who is sponsoring clinical trial NCT07155057?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07155057 being conducted?
This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease (DED)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
COMPLETED · Phase 3
-
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
COMPLETED · Phase 3
-
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.